Streck E L, Edom P T, Noriler M E, Borges L F, Pontes Z L, Parolo E, Dutra-Filho C S, Wannmacher C M, Wyse A T
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Metab Brain Dis. 2000 Jun;15(2):105-14. doi: 10.1007/BF02679977.
Na+, K+-ATPase activity was measured in synaptic plasma membrane from cerebral cortex of Wistar rats subjected to experimental phenylketonuria, i.e., chemical hyperphenylalaninemia induced by subcutaneous administration of 5.2 micromol phenylalanine / g body weight (twice a day) plus 0.9 micromol p-chlorophenylalanine / g body weight (once a day). The treatment was performed from the 6th to the 14th postpartum day and rats were killed 12 h after the last injection. Synaptic plasma membrane from cerebral cortex was prepared by a discontinuous density sucrose gradient for Na+, K+-ATPase activity determination. The results showed that the enzyme activity was decreased by 30% in animals subjected to experimental phenylketonuria when compared to control. The in vitro effects of the drugs on Na+, K+-ATPase activity were also investigated. Phenylalanine and p-chlorophenylalanine inhibited the enzyme activity and this inhibition was reversed by alanine. In addition, competition between phenylalanine and p-chlorophenylalanine for binding to the enzyme was observed, suggesting a common binding site for these substances. Our results suggest that reduction of Na+, K+-ATPase activity may be one of the mechanisms related to the brain dysfunction observed in human PKU.
对接受实验性苯丙酮尿症的Wistar大鼠大脑皮质突触质膜中的钠钾ATP酶活性进行了测定,即通过皮下注射5.2微摩尔苯丙氨酸/克体重(每天两次)加0.9微摩尔对氯苯丙氨酸/克体重(每天一次)诱导化学性高苯丙氨酸血症。从产后第6天至第14天进行该治疗,在最后一次注射后12小时处死大鼠。通过不连续密度蔗糖梯度制备大脑皮质的突触质膜以测定钠钾ATP酶活性。结果显示,与对照组相比,接受实验性苯丙酮尿症的动物中该酶活性降低了30%。还研究了药物对钠钾ATP酶活性的体外作用。苯丙氨酸和对氯苯丙氨酸抑制该酶活性,而丙氨酸可逆转这种抑制作用。此外,观察到苯丙氨酸和对氯苯丙氨酸之间存在与该酶结合的竞争,表明这些物质具有共同的结合位点。我们的结果表明,钠钾ATP酶活性降低可能是人类苯丙酮尿症中观察到的脑功能障碍相关机制之一。